Get the Stockscreener App
5.39
0.65%
0.035
Valneva Se Adr stock is traded at $5.39, with a volume of 14,958.
It is up +0.65% in the last 24 hours and down -5.11% over the past month.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
See More
Previous Close:
$5.355
Open:
$5.47
24h Volume:
14,958
Relative Volume:
0.17
Market Cap:
$511.10M
Revenue:
$180.81M
Net Income/Loss:
$-160.71M
P/E Ratio:
-2.8779
EPS:
-1.8729
Net Cash Flow:
$-88.46M
1W Performance:
+1.03%
1M Performance:
-5.11%
6M Performance:
-37.33%
1Y Performance:
-10.11%
1-Day Range:
$5.3001
$5.47
1-Week Range:
$5.1332
$5.50
52-Week Range:
$5.06
$12.25
Valneva Se Adr Stock (VALN) Company Profile
Compare VALN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VALN
Valneva Se Adr
|
5.39 | 511.10M | 180.81M | -160.71M | -88.46M | -1.8729 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Valneva Se Adr Stock (VALN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Downgrade | Goldman | Neutral → Sell |
| Aug-19-25 | Resumed | H.C. Wainwright | Buy |
| Aug-03-22 | Initiated | H.C. Wainwright | Buy |
Valneva Se Adr Stock (VALN) Latest News
VALN Q1 2026 Earnings: Significant EPS Miss Highlights Development‑Stage Cash BurnEstimate Dispersion - newsline.com
VLA.PA Technical Analysis | Trend, Signals & Chart Patterns | VALNEVA SE (EPA:VLA) - ChartMill
VALNEVA:Declaration of shares and voting rights - GlobeNewswire Inc.
VALN Q1 2026 Earnings: Significant EPS Miss Drives Stock DeclineEarnings Acceleration Picks - newsline.com
Valneva (VALN) Holds Steady Near Support as Traders Weigh Near-Term CatalystsMarket Cap Weight - The Legal Advocate
VLA.PA Stock Price, Quote & Chart | VALNEVA SE (EPA:VLA) - ChartMill
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Valneva SE earnings missed by $0.24, revenue fell short of estimates - Investing.com
Valneva Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Valneva SE Q1 2026 reports revenue decline, stock dips - Investing.com Nigeria
Earnings call transcript: Valneva SE Q1 2026 reports revenue decline, stock dips By Investing.com - Investing.com South Africa
Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Investors to Connect - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SEVALN - PR Newswire
Valneva’s €84M Cash Injection Comes With a Bitter Pill for Shareholders - AD HOC NEWS
Valneva shares slide after US pullback on chikungunya vaccine filing - MSN
Valneva (NASDAQ:VALN) Sets New 12-Month Low After Analyst Downgrade - MarketBeat
Valneva SE Sponsored ADR (NASDAQ:VALN) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Goldman Sachs downgrades Valneva stock rating to sell on Lyme vaccine uncertainty - Investing.com
Valneva (NASDAQ:VALN) Shares Gap UpTime to Buy? - MarketBeat
Valneva's Dual Challenge: Legal Scrutiny Meets Commercial Reality - AD HOC NEWS
Guggenheim cuts Valneva stock price target to $11 on Lyme vaccine - Investing.com
Valneva SE Under Investigation for Securities Fraud - Intellectia AI
VALN stock nosedives on mixed results from Lyme disease vaccine study - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Valneva (NASDAQ:VALN) Shares Gap DownHere's Why - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Valneva SE (VALN) And Encourages Shareholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Valneva SE (VALN) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Valneva Faces Mounting Legal Pressure Following Clinical Trial Setback - AD HOC NEWS
2026-04-06 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Valneva SE (VALN) and Encourages Shareholders to Learn More About the Investigation | NDAQ:VALN | Press Release - Stockhouse
Valneva's Travel Vaccines: Strategic Pivot to Emerging Markets Drives Long-Term Investor Value in Bi - AD HOC NEWS
Valneva SE (VALN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Declaration of shares and voting rights of Valneva SE – March 2026 - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Encourages Valneva SE (VALN) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Valneva Se Adr Stock (VALN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):